AU2729400A - Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease - Google Patents

Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease

Info

Publication number
AU2729400A
AU2729400A AU27294/00A AU2729400A AU2729400A AU 2729400 A AU2729400 A AU 2729400A AU 27294/00 A AU27294/00 A AU 27294/00A AU 2729400 A AU2729400 A AU 2729400A AU 2729400 A AU2729400 A AU 2729400A
Authority
AU
Australia
Prior art keywords
alzheimer
diagnosis
disease
treatment
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27294/00A
Inventor
James Daly
Girish J. Kotwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of AU2729400A publication Critical patent/AU2729400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU27294/00A 1999-01-19 2000-01-19 Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease Abandoned AU2729400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11632899P 1999-01-19 1999-01-19
US60116328 1999-01-19
PCT/US2000/001115 WO2000043027A1 (en) 1999-01-19 2000-01-19 Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease

Publications (1)

Publication Number Publication Date
AU2729400A true AU2729400A (en) 2000-08-07

Family

ID=22366532

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27294/00A Abandoned AU2729400A (en) 1999-01-19 2000-01-19 Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease

Country Status (2)

Country Link
AU (1) AU2729400A (en)
WO (1) WO2000043027A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US20070116672A1 (en) * 2003-09-05 2007-05-24 Kotwal Girish J Treatment of rheumatic diseases
WO2006131874A2 (en) * 2005-06-06 2006-12-14 Univ Cape Town Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
CA2655371C (en) 2006-06-15 2017-06-20 Eastern Virginia Medical School Methods for regulating complement cascade proteins using astrovirus coat protein and derivatives thereof
US8834409B2 (en) 2008-07-29 2014-09-16 Covidien Lp Method for ablation volume determination and geometric reconstruction
US8906845B2 (en) 2010-07-21 2014-12-09 Eastern Virginia Medical School Peptide compounds to regulate the complement system
US10005818B2 (en) 2010-07-21 2018-06-26 Realta Holdings, Llc Derivative peptide compounds and methods of use
US10947279B2 (en) 2015-06-26 2021-03-16 Realta Holdings, Llc Synthetic peptide compounds and methods of use
US10933116B2 (en) 2015-06-26 2021-03-02 Realta Holdings, Llc Synthetic peptide compounds and methods of use
CN111511403A (en) * 2017-12-28 2020-08-07 学校法人兵库医科大学 Lipocalin-type prostaglandin D2 synthase production promoter
WO2019139886A1 (en) 2018-01-09 2019-07-18 Realta Holdings, Llc Pic1 inhibition of myeloperoxidase oxidative activity in an animal model

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609647A (en) * 1985-05-28 1986-09-02 Massachusetts Institute Of Technology Cytidyl diphosphocholine-drug composition and process
US5157110A (en) * 1988-08-20 1992-10-20 The Government Of The United States Of America Synthetic, anti-complement protein
US5855882A (en) * 1995-04-05 1999-01-05 The Picower Institute For Medical Research Methods for inhibiting the cross-linking of advanced glycosylation endproducts

Also Published As

Publication number Publication date
WO2000043027A1 (en) 2000-07-27

Similar Documents

Publication Publication Date Title
AU2001249835A1 (en) Diagnosis and treatment of alzheimer's disease
AU1407399A (en) Treatment for alzheimer's disease
AU1516301A (en) Use of a milk protein hydrolysate in the treatment of diabetes
AU4054297A (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
HUP0103654A2 (en) Use of smilagenin and anzurogenin-d for production of pharmaceutical compositions for the treatment of alzheimer's disease
AU5508798A (en) Diagnostic and therapeutic reagents for alzheimer's disease
EP1392287B8 (en) Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
EP1249498A3 (en) Alzheimer's disease secretase, APP substrates therefor, and uses therefor
AU2865000A (en) Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
EP1007048A4 (en) Identification of agents for use in the treatment of alzheimer's disease
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU3279395A (en) Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
IL141507A0 (en) Pharmaceutical agents for the treatment of parkinson's disease, adhd and microadenomas
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
AU2729400A (en) Application of a viral complement inhibitory protein in the treatment and diagnosis of alzheimer's disease
NO20001869D0 (en) Procedures for the treatment of Alzheimer's disease
AU2002222108A1 (en) Diagnosis and treatment of alzheimer's disease
AU5550800A (en) Diagnosis and treatment of alzheimer's disease
AU5053296A (en) Pharmaceutical agents for the treatment of Alzheimer's disease
AU1405899A (en) Treatment for alzheimer's disease
AU2002357232A1 (en) Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
AU5876899A (en) Polymorphisms in the human alpha4 integrin subunit gene, suitable for diagnosis and treatment of integrin ligand mediated diseases
FR2774596B1 (en) USE OF SELENATED COMPOUNDS IN THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase